Yanling Xiao

5PUBLICATIONS
41CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 18, 2026
Regulation of immune checkpoint molecules in cancer immune evasion and therapy.

|Mar 01, 2026
Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response.

Mo D Staal, Zhixian Wang, Douwe M T Bosma

|Dec 10, 2025
Erythropoietin receptor on cDC1s dictates immune tolerance.

Xiangyue Zhang, Christopher S McGinnis, Guotao Yu

|Jan 13, 2023
CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment.

Xin Lei, Indu Khatri, Tom de Wit

|Apr 02, 2021
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir

Pageof 1

Frequent Collaborators

3 joint publications

Jannie Borst

1 joint publications

Jesper van Eck van der Sluijs

1 joint publications

Diede van Ens

1 joint publications

Soley Thordardottir